Two immunotherapies before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two immunotherapy drugs (ficerafusp alfa and pembrolizumab) given before surgery for advanced head and neck cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed, advanced head and neck cancer (mouth, throat, voice box, or hypopharynx) that can be removed with surgery.
- Your tumor must be PD-L1 positive (a protein that helps immunotherapy work).
- You haven't had prior treatment with certain immunotherapies or EGFR-targeted drugs.
- You are 18 or older and in generally good health (ECOG 0 or 1, meaning you can do daily activities without much help).
- You are willing to provide blood and tumor samples before and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
This study tests two drugs (pertuzumab and lenvatinib) given together before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve outcomes for patients who haven't received prior cancer treatment.
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
This trial tests a combination of two new drugs (ficerafusp alfa and pembrolizumab) along with focused radiation therapy for newly diagnosed head and neck cancer that hasn't spread widely. The goal is to shrink the cancer before surgery and potentially improve survival.
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
This trial tests a combination of two drugs (ficerafusp alfa and nivolumab) to treat head and neck squamous cell carcinoma that has come back or worsened after platinum chemotherapy. The drugs work by helping your immune system fight cancer cells.
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.